FDA Holds Off Approval of New Merck Drug
As expected, the FDA is holding off on Merck’s new COX-2, Arcoxia. I’ve been bombarded with ads saying it’s “coming soon”. I guess not.
ADVERTISEMENT
More in Uncategorized
Past Week
-
Health care as a human right vs. commodity: Resolving the paradox
-
My wife’s story: How DEA and CDC guidelines destroyed our golden years
-
Why voicemail in outpatient care is failing patients and staff
-
Stopping medication requires as much skill as starting it [PODCAST]
-
The health insurance crisis 2026: What Kentuckians need to know
-
Post-stroke cognitive impairment: the hidden challenge of recovery
-
Past 6 Months
-
How environmental justice and health disparities connect to climate change
-
Will AI replace primary care physicians?
-
A physician father on the Dobbs decision and reproductive rights
-
What is the minority tax in medicine?
-
Why the U.S. health care system is failing patients and physicians
-
Alex Pretti: a physician’s open letter defending his legacy
-
Recent Posts
-
The health insurance crisis 2026: What Kentuckians need to know
-
Weaponizing food allergies in entertainment endangers lives [PODCAST]
-
Geriatric diabetes management: Why strict A1c targets can harm seniors
-
Why progression independent of relapse activity is the silent driver of disability in multiple sclerosis
-
Why medical school DEI mission statements matter for future physicians
-
A physician’s quiet reflection on January 1, 2026
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
